Background
Oropharyngeal candidiasis is among the most common opportunistic infections observed in HIV-infected individuals and often presents as the initial manifestation of disease [1] [2] [3] [4] . Left untreated, oropharyngeal candidiasis can contribute to morbidity including esophageal disease and weight loss [5] . Recent studies conducted by the Oral HIV AIDS Research Alliance (OHARA) of the AIDS Clinical Trials Group (ACTG) demonstrated that oropharyngeal candidiasis is strongly associated with tuberculosis in HIV-infected participants, independent of CD4 þ cell count [6] . Although the incidence of oropharyngeal candidiasis has declined in resource-rich countries following the introduction of HAART [7, 8] , the prevalence of oropharyngeal candidiasis in HIVinfected participants in resource-limited settings (RLSs) remains substantial, reaching as high as 33% [9] [10] [11] [12] [13] [14] .
Nystatin oral suspension (NYS) is the main antifungal used to treat oropharyngeal candidiasis in HIV-infected participants in RLS [15] [16] [17] [18] . To identify a low-cost alternative to current treatment, our group conducted preclinical studies and found that gentian violet possesses potent anti-Candida activity [19, 20] . Gentian violet has been recommended by the WHO as a topical treatment for oropharyngeal candidiasis in HIV-infected participants, at a concentration of 1% [21] . In an earlier study, our group reported that oral rinsing with gentian violet at low concentrations (0.00165%, 16.5 mg/ml) was safe and well tolerated, with no mucosal staining [22] . In the present study, we compared the safety and efficacy of topical gentian violet with that of NYS in the treatment of oropharyngeal candidiasis in HIV-infected adult participants from RLS.
Methods
Design A5265 was a multicenter phase III, randomized, openlabel, evaluator-blinded clinical trial conducted in eight non-US Clinical Research Sites (CRSs) of the ACTG (detailed clinical protocol is provided as a Supplemental File, http://links.lww.com/QAD/A994). Evaluation of signs and symptoms of oropharyngeal candidiasis was performed by a trained clinician blinded to the treatment assignment.
Study sites
The sites participating in the protocol A5265 were University of Natal, Durban At each site, the study protocol and consent form were approved as appropriate by their local institutional review board.
Study population
The eligibility criteria for enrollment were as follows: HIV-infected adults (!18 years of age) presenting with pseudomembranous candidiasis ; positive identification of Candida in oral swabs at screening; negative pregnancy test performed within 48 h prior to study entry for female study volunteers of reproductive age; and a Karnofsky performance score at least 60 prior to entry [23] , with ability to comply with all study procedures and follow-up after informed consent. Participants were excluded for the following reasons: proven or presumptive esophageal candidiasis at study entry, use of any investigational drug within 30 days prior to study entry, concurrent vaginal candidiasis within 21 days prior to study entry, use of inhaled or systemic corticosteroids or antifungals within 14 days prior to study entry, use of antifungal agents or other oral topical treatments during the study period, allergy/sensitivity or any hypersensitivity to gentian violet or NYS, active illicit drug or alcohol use or dependence that would interfere with adherence to study requirements, serious illness (HIV-1 associated or not) indicating a high likelihood of death in the 30 days after study entry, predictors of early mortality (e.g. anemia, low CD4 þ cell count), previous or current history of porphyria, presence of oral warts during the screening period or at study entry, or use of full or partial dentures at study entry. Participants who failed treatment were referred for care outside of the study but continued to be followed on study; azole therapy was most often initiated with study drug failure.
Randomization and stratification
Participants were randomized in a 1 : 1 ratio to two arms (gentian violet or nystatin) and stratified according to the following criteria: screening CD4 þ cell count more than 200 cells/ml or 200 cells/ml or less, and taking antiretroviral therapy (ART) at the time of study entry or not taking ART at the time of study entry (and not planning to initiate ART during the study-defined 14-day treatment period).
Study treatment
At randomization, participants were stratified by CD4 þ T-cell counts (>200 cells/ml or 200 cells/ml) and ART use at the time of study entry ('Yes' or 'No') to receive topical gentian violet (0.00165%, 5 ml swish and gargle for 2 min and expectorate twice daily) or NYS oral suspension (5 ml of 100 000 unit/ml swish for 2 min and swallow, four times daily) for 14 days. Participants were instructed not to eat or drink for 30 min before and after the administration of study drugs.
Oral examination and scoring of lesions
The oral cavity was categorized into six sites (Supplementary Fig. 1 , http://links.lww.com/QAD/A994). Severity was scored from 0 to 3 (0: no lesions, 1: scattered nonconfluent lesions <2 mm in diameter, 2: multiple nonconfluent lesions >2 mm in diameter, and 3: extensive confluent lesions). A composite severity score (CSS, range: 0-18) was obtained after adding the scores from all six sites. All examiners received standardized training in establishing a clinical diagnosis of pseudomembranous candidiasis using a published case definition [24] . A primary physician assisted by a registered nurse practitioner led the assessment at each study site.
Endpoints
The primary endpoint was a single binary outcome, defined as cure (CSS ¼ 0) or improvement (a decrease in severity of lesions) at the end of treatment. Therapy was considered to have failed if participants had no improvement or worsening of their scores, or if signs or symptoms worsened after at least 7 consecutive days of therapy.
Secondary endpoints
Secondary endpoints included oropharyngeal candidiasis symptoms (discomfort and pain), yeast colony counts, adverse events, tolerance, adherence (medication diaries and bottle counts), self-reported quality of life (QOL), acceptability of study drugs, and cost per treatment regimen. Discomfort and pain were rated on a 4-point scale (from no pain ¼ 0, mild pain ¼ 1, moderate pain ¼ 2, and severe pain ¼ 3). Cost per treatment course was calculated using a microcosting, ingredients-based approach [25] . Self-reported resource utilization including outpatient clinic visits and inpatient hospital stays at study entry and at the week-6 visit was compared between each arm. Costs for NYS also included materials and labor costs for drug preparation if acquired in concentrated form. Drug acquisition and labor costs were obtained directly from study sites and converted to 2014 US Dollars.
Sample size calculations and data analyses
The current study was sized to estimate the difference in clinical efficacy rates between gentian violet and NYS for the treatment of oropharyngeal candidiasis with appropriate precision [width of 95% confidence interval (CI) <0.2]. Repeated CIs were used to control type I error. One interim analysis was conducted by utilizing a 99.7% CI, and the final analysis used a 95.1% CI (constructed based on the Lan-DeMets error-spending function corresponding to the O'Brien-Fleming boundary). Assuming response rates of gentian violet and NYS of 50% (resulting in the greatest variation and hence the widest CI), an intention-to-treat population (ITT) analysis required 494 participants after adjusting for 10% noncompliance.
The primary analysis was conducted on a modified ITT population, which was defined as participants who present with a clinical diagnosis of oropharyngeal candidiasis with a positive yeast culture for Candida spp. at baseline. Cases without oral exam records at week 2 were considered as clinical failures. A comparison of clinical efficacy rates was performed using a 95.1% CI for the difference (reported as 95% to account for 95% simultaneous coverage probability given one interim analysis) between two proportions, with four subgroup analyses conducted on the basis of two stratification factors (screening CD4
þ cell count and ART use at the time of study entry). In addition, a comparison of cure rates was performed per the Data Safety Monitoring Board (DSMB) recommendation of using 'cure' as the primary endpoint given the concern of staining with gentian violet. The CIs were based on either asymptotic method when event counts were more than 12 or the formula provided in Fleiss et al. [26] , in which the CI was adjusted by 0.5 Â (1/n 1 þ 1/n 2 ). These comparisons were also conducted on the basis of observed data as sensitivity analyses.
Study accrual and closure A5265 was opened to accrual on 7 June 2011, and the first participant was enrolled on 2 August 2011. As of 19 October 2012, a total of 221 participants (targeted sample size ¼ 494) were enrolled. The study was halted because of the DSMB concern regarding the excessive mortality unrelated to study medications in the recruited population, and subsequently the study was closed because OHARA funding was not renewed.
Results

Baseline characteristics
Summaries of selected baseline characteristics are shown in Table 1 . A total of 221 participants were enrolled into the study (Fig. 1) ; 181 participants completed the study protocol and 40 participants discontinued the study prior to study completion (refer to Table 2 for reasons of study discontinuation). Among the enrolled participants, 106 (48%) were in the age group 30-39 years, and 128 (58%) were women. Moreover, 203 (92%) participants were black non-Hispanic, and 18 (8%) were Asian or Pacific Islanders. At the time of study entry, 166 (75%) participants were not taking ART and not planning to initiate ART until the study-defined 14-day treatment period was complete. The CD4 þ cell count in 175 participants (79%) was between 0 and 200 cells/ml (median: 53 cells/ml), and the median of baseline viral RNA titer log 10 [HIV RNA (copies/ml)] was 5.30. In patients with CD4
þ cell counts below 200 cells/ml, the 
Safety monitoring
There were 18 participants (10 in gentian violet group and eight in NYS group) who experienced any signs or symptoms of grade 3 or higher adverse events and 12 participants (six in gentian violet and six in NYS) who experienced new laboratory toxicity events of grade 3 or higher. In the gentian violet arm, one case was reported to be probably not related to gentian violet, whereas all other new signs, symptoms, laboratory events, and adverse events were not related to gentian violet. In the NYS arm, there were two reported cases probably not related, one case possibly related, and the rest (three) were not related to the study drug.
There were 21 deaths (12 in gentian violet and nine in NYS), and the primary causes of death for 18 of these cases were HIV infection or HIV-related diagnosis (15), non-HIV diagnosis (two), and toxicity (one) secondary to herbal medication (Table 3) . None of the deaths were considered related to study medications.
Efficacy analysis
Population for efficacy analysis Of the 221 participants enrolled, a total of 182 (gentian violet: 92; NYS: 90) had positive Candida culture results at baseline and were eligible for the modified ITTefficacy analysis (Fig. 1) . Of these participants, 170 (gentian violet: 87; NYS: 83) had oral exams at week 2. Cases without oral exam records at week 2 were considered as clinical failures, which included five participants in the gentian violet arm and seven in the NYS arm. For the 'observed data' analysis, 19 (gentian violet: 10; NYS: nine) of the 221 (gentian violet: 110; NYS: 111) enrolled participants did not have oral exams at week 2, thus excluded, which led to a total of 202 (gentian violet: 100; NYS: 102) participants in the analysis (Fig. 1) .
Evaluation of clinical efficacy
We first evaluated the difference in clinical efficacy rates based on modified ITT analysis. Among the 182 participants eligible for analysis, 63 (68.5%) in the gentian violet arm (n ¼ 92) had cure or improvement of oropharyngeal candidiasis compared with 61 (67.8%) in the NYS arm (n ¼ 90), resulting in a nonsizable difference (gentian violet-NYS) of 0.007 (95% CI: À0.129, 0.143). Table 1 showed that the majority of participants were not on ART. Comparison of the two arms using a 'cure' rate also showed no sizable difference (À0.0007, 95% CI: À0.146, 0.131). Sensitivity analyses based on observed data showed no sizable difference either (Table 4 ). Due to the sparse stratum cells presented in Table 4 , no adjustment was made for the stratification in the efficacy analyses or the additional analyses below.
Additional outcome measures by treatment
The analyses below were based on observed data.
Staining Evaluation of differences in staining of the oral mucosa in the gentian violet arm revealed that 61% of participants reported no staining, 28% reported mild staining (mainly the tongue), and 11% reported moderate staining of the oral cavity. Notably, no participant reported severe staining. There were no instances in which gentian violet was discontinued due to staining. No staining was observed in the NYS arm.
Evaluation of symptoms
Pain and discomfort associated with oropharyngeal candidiasis were evaluated at study entry, end of treatment, and at clinical relapse. At study entry, a total of 217 observations (106 in the gentian violet arm and 111 in the NYS arm) were available for evaluation. At the end of treatment, a total of 204 observations were available to evaluate the symptoms using extended Mantel-Haenszel test between arms. The tests did not show a sizable treatment effect. A total of eight participants had clinical relapse of oropharyngeal candidiasis between weeks 2 and 8 (five in gentian violet and three in NYS). All five participants reported no pain in the gentian violet arm, whereas two reported mild and one reported severe pain in the NYS arm. One participant from each arm reported severe discomfort at relapse; others had no discomfort.
Quantitative yeast colony counts
The number of colony-forming-units (CFUs) per milliliter was evaluated at entry, end of treatment, at week 6, and at clinical relapse (between weeks 2 and 8).
The difference in the means of log-transformed CFUs at entry (gentian violet-NYS, 95% CI), end of treatment, and at week 6 was 0.25 (À0.40, 0.89), 1.05 (0.32, 1.78),
Treatment of oral candidiasis Mukherjee et al. 85 Table 3 . Reasons for death in gentian violet and nystatin oral suspension treatment arms. None of the deaths were considered related to study medications. GV, gentian violet; NYS, nystatin oral suspension. and 1.15 (À0.88, 1.17), respectively (Supplemental Table  1 , http://links.lww.com/QAD/A994). At clinical relapse, three observations were available for each arm without marked difference in mean log CFU.
Assessment of tolerance, adherence, quality of life, acceptability, and cost comparison There was no significant difference between the gentian violet and NYS groups in regard to drug tolerance, adherence, self-reported QOL, and acceptability (P ¼ 0.17, 0.83, 0.88, and 0.36, respectively). The estimated ratio of adherence between gentian violet and NYS was 1.01 with 95% CI (0.93, 1.10), and the ratio of acceptability between the two groups was 1.03 with 95% CI (0.97, 1.10). Comparison of the cost per treatment course of gentian violet and NYS by study CRS showed that the gentian violet medication (requiring pharmacy preparation via reconstitution and/or dilution), procurement costs were sizably lower than treatment with NYS (no pharmacy preparation needed) [median (Q1, Q3) ¼ $2.51 (0.95, 3.11) and $19.42 (6.46, 36.28) , respectively, P ¼ 0.01; Supplementary Fig. 2 and Supplementary Table 2 , http://links.lww.com/QAD/A994].
Discussion
The current study was the largest evaluator-blinded, randomized clinical trial that compared the efficacy of gentian violet with NYS in the treatment of oropharyngeal candidiasis in HIV-infected adults in RLS. Our results showed that both treatments resulted in high clinical efficacy rates with no sizable differences between the two groups. The efficacy rates for both gentian violet and NYS were higher than previous studies comparing the efficacy of these two agents [27, 28] . Our secondary analyses revealed no sizable differences in tolerance, adherence, QOL, or acceptability of study drugs.
Oral NYS is commonly used in the treatment of oropharyngeal candidiasis in HIV-infected participants [29, 30] ; however, its use is limited by bitter taste, gastrointestinal side effects, four times per day dosing, and a relatively high cost, which contribute to reduced drug adherence and lower efficacy. Although there is substantial variation in procurement prices for medications across sites [31] , our study showed that gentian violet (despite required pharmacy preparation) was consistently associated with a lower cost per treatment dose compared with NYS (no pharmacy preparation needed). Although labor needs may constrain health care in RLS, the need for pharmacy preparation for gentian violet is counterbalanced by the substantially lower cost of gentian violet. For example, the labor cost of preparing gentian violet would need to be more than seven times the current estimates before total cost per gentian violet treatment regimen reached that of NYS. In addition, the widespread availability of gentian violet in RLS, its longterm physical and chemical stability, and the ease of preparation makes gentian violet a viable and attractive treatment option in HIV-infected participants.
Nyst et al. [27] conducted a randomized open-label study to compare the efficacy of gentian violet versus NYS and oral ketoconazole for the treatment of oropharyngeal candidiasis in AIDS participants in the Democratic Republic of Congo. There was similar efficacy among all three drugs. However, this study was limited by the small sample size and the fact that the gentian violet concentration used was 300-fold higher than the concentration used in the current study (0.5 versus 0.00165%, respectively) and was associated with staining of teeth and gums, oral irritation, and small superficial ulcers. In a separate study, Hodgson et al. [28] compared the efficacy and tolerability of 1 and 0.00165% (as used in this study) gentian violet and NYS mouth rinses for oral pseudomembranous candidiasis in pediatric HIV-infected participants in Malawi. The lower concentration of gentian violet (0.00165%) was as effective as a 1% gentian violet solution with fewer side effects.
Gentian violet has a long history of use and has been recommended by the WHO as a topical treatment for oropharyngeal candidiasis in HIV-infected participants, at a concentration of 1% [21] . However, as 1% gentian violet strongly stains the oral cavity, its use has been associated with a stigmatizing effect. The current trial convincingly demonstrated that use of a lower concentration of gentian violet does not lead to severe staining or discontinuation of gentian violet treatment and that any staining noted was transient and generally mild. These results may provide an impetus for wider acceptance of gentian violet as a treatment for oropharyngeal candidiasis, especially in RLS.
Deaths reported among enrolled participants in the current study that served as the basis for the DSMB halt of the study are reflective of the study population and not associated with study medications. In this regard, mortality rates of 8-40% have been reported in HIV/ AIDS participants in the era of ART in RLS [32] [33] [34] [35] [36] .
The median CD4 þ cell count of 53 cells/ml for study participants in our study may help explain the deaths in this patient population.
Limitations of the study include the inability to fully accrue the target enrollment, leading to a wider CI (0.27 using the estimated efficacy rates) when compared with the original design (0.20 assuming 50% response rates). In addition, this study was limited to sub-Saharan Africa and India, and the generalization of results to other geographic sites needs to be confirmed in additional clinical trials.
In conclusion, this is the largest randomized clinical trial evaluating the use of gentian violet for treatment of oral candidiasis in HIV-infected adults in RLS. Although the efficacy of gentian violet was not statistically different than nystatin, it was well tolerated and drug procurement was substantially less costly than nystatin for treatment of HIV-associated oral candidiasis.
